

Nutrition with Gastrostomy Feeding Tubes for Amyotrophic Lateral Sclerosis in Canada

Timothy Benstead, Caitlin Jackson-Tarlton, Desmond Leddin

ABSTRACT: *Background:* Amyotrophic lateral sclerosis (ALS) is a rapidly progressing degenerative motor neuron disease that results in significant muscle weakness. Defects in energy metabolism and difficulties in swallowing eventually lead to a reduction in body mass. Weight loss exacerbates symptoms and serves as an independent negative prognostic factor. Percutaneous endoscopic gastrostomy (PEG) is often inserted in patients with ALS to either supplement or replace oral feeding. However, the criteria for PEG placement and timing of insertion are important clinical decisions that have not been fully studied. Given the absence of guiding evidence, the aim of this project was to better understand how Canadian ALS clinics make decisions regarding gastrostomy feeding. *Methods:* ALS clinical directors across Canada were asked if they had written guidelines for timing of PEG insertion and if not, what criteria they use to make this decision. Responses from 10 of 17 centres contacted were received. *Results:* The approach to supplemental nutrition management in Canadian clinics varies in the absence of formal guidelines. Only one centre has a written set of centre-specific protocols in place. Most clinics considered some combination of respiratory decline, weight loss, dysphagia and/or patient readiness when reaching a decision. However, the absolute threshold and mechanism of measuring the individual criteria differed between clinics. *Conclusions:* Practices generally reflect international published recommendations but vary on the emphasis of specific criteria. Further research is required to determine the optimal timing and criteria to place gastrostomy feeding tubes in the ALS population.

RÉSUMÉ: *Alimentation par sonde de gastrostomie chez les patients atteints de sclérose latérale amyotrophique au Canada. Contexte :* La sclérose latérale amyotrophique (SLA) est une maladie dégénérative progressive du neurone moteur qui entraîne une faiblesse musculaire importante. Les anomalies du métabolisme énergétique et les difficultés à avaler causent éventuellement une diminution de la masse corporelle. La perte de poids exacerbe les symptômes et constitue un facteur pronostique négatif indépendant. On a souvent recours à la gastrostomie percutanée endoscopique (GPE) chez les patients atteints de SLA, soit pour fournir un supplément alimentaire ou pour remplacer l'alimentation par voie orale. Cependant, les critères utilisés pour avoir recours à la GPE et le moment d'y avoir recours sont des décisions cliniques importantes qui n'ont pas encore été étudiés à fond. Étant donné l'absence de données pouvant orienter la décision, le but de ce projet était de mieux comprendre comment la décision d'avoir recours à la GPE est prise dans les cliniques canadiennes de SLA. *Méthodologie :* Nous avons demandé aux directeurs de cliniques de SLA à travers le Canada s'ils avaient des directives écrites pour déterminer le moment d'avoir recours à la GPE et si ce n'est pas le cas, quels critères ils utilisaient pour prendre cette décision. Nous avons reçu des réponses de 10 des 17 centres que nous avons contactés. *Résultats :* L'approche à la gestion de la supplémentation nutritionnelle dans les cliniques canadiennes demeure variable en raison de l'absence de lignes directrices formelles. Un seul centre avait mis en place ses propres protocoles écrits à ce sujet. La plupart des cliniques considéraient différentes combinaisons de facteurs, soit le déclin respiratoire, la perte de poids, la dysphagie et/ou si le patient est prêt à subir cette intervention au moment où la décision est prise. Cependant, le seuil absolu et le mécanisme de mesure des critères individuels étaient différents d'une clinique à l'autre. *Conclusions :* Les pratiques des différentes cliniques reflètent en général les recommandations internationales publiées, mais elles varient concernant l'emphasis mise sur des critères spécifiques. Il faudra procéder à des études supplémentaires pour déterminer le moment optimal et les critères à utiliser pour la mise en place de sondes d'alimentation par gastrostomie chez les patients atteints de SLA.

Keywords: amyotrophic lateral sclerosis, dysphagia, respiratory, neurological practice, swallowing

doi:10.1017/cjn.2016.28

Can J Neurol Sci. 2016; 43: 796-800

Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease resulting from the death of upper and lower motor neurons in the motor cortex, brain stem and spinal cord. This results in rapidly progressive muscle weakness, atrophy, and spasticity. Bulbar and respiratory muscle involvement can lead to dysphagia and dyspnea. In addition to the management of neuromuscular symptoms, nutritional and respiratory management are important aspects in the treatment of ALS.

Weight loss and dysphagia are frequent features of ALS and influence prognosis. The etiology of weight loss is multi-factorial. Upon initial diagnosis, patients with ALS are generally lean with a

normal or low body-mass index (BMI).¹ Patients then typically become malnourished and lose body fat as the disease progresses resulting in a further reduction in BMI.²⁻⁴

From the Division of Neurology (TB); Division of Gastroenterology (DL); Department of Medicine; Undergraduate Medicine (CSJ); Dalhousie University, Halifax, Canada.

RECEIVED AUGUST 28, 2015. FINAL REVISIONS SUBMITTED DECEMBER 7, 2015. DATE OF ACCEPTANCE JANUARY 29, 2016.

Correspondence to: Timothy Benstead, Room 3828, Halifax Infirmary, 1796 Summer Street, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia B3H 3A7. E-mail: tbenstea@dal.ca.

The reason for progressive weight loss is two-fold; a decrease in energy intake is coupled with an increase in energy expenditure. Cranial bulbar muscle weakness producing dysphagia increases the risk for insufficient caloric intake; patients often eat more slowly and become fatigued during meals.⁵ Patients with ALS have a high basal metabolism rate contributing to weight loss.⁶⁻⁷ The mechanism leading to hypermetabolism is currently unknown, but has been demonstrated in both the sporadic and familial forms of ALS.⁶⁻⁸ A loss of body mass and malnutrition are associated with faster progression of the disease and are independent prognostic factors.^{5,9-13} Of additional concern, are the safety issues of aspiration and choking that result from dysphagia.

Nutritional interventions are integral to the management of ALS. At the onset of dysphagia the initial steps involve counseling by dietitians, modification of food and fluid consistency, prescription of high-protein and high-caloric supplements, and education of the patient on feeding and swallowing techniques. However, if significant caloric reduction or aspiration risk develops, a gastrostomy feeding tube is often introduced. Both the American Academy of Neurology (AAN) and the European Federation of Neurological Sciences (EFNS) have published guidelines recommending the placement of percutaneous endoscopic gastrostomy (PEG) in patients with ALS in order to supplement nutrition. This recommendation was based on evidence that nutritional supplementation using PEG was helpful for stabilizing weight loss.¹⁴⁻¹⁶ The prevention in weight-loss provided by PEG likely translates to a survival benefit but there is not enough data to quantify to what extent this occurs.¹⁶

In addition to general procedural risks for PEG, such as wound infection, bleeding and ulceration, there are risks specific to the ALS population. Patients with respiratory muscle impairment undergoing sedation may have aspiration with PEG insertion.¹⁷ Diaphragmatic weakness causes a “high-riding” stomach, in which the stomach lies under the ribs, which can increase the difficulty of tube insertion.¹⁸ Furthermore, ALS is known to be a rapidly progressing disease. Thus the timing and the method of insertion are important considerations when using gastrostomy feeding in the management of ALS. However, both these topics are under-studied. As a result, the AAN and EFNS have each stated that there is insufficient evidence to support or refute specific timing of PEG insertion in patients with ALS. That said, the AAN practice parameter does suggest consideration of dysphagia, weight loss and respiratory function, measured as forced vital capacity (FVC), in the decision making process.

Given the lack of evidence to rigorously guide decisions and the presence of international guidelines, we wished to determine how Canadian ALS clinics make decisions regarding the timing and placement of gastrostomy feeding tubes in patients with ALS.

METHODS

Through email and paper correspondence we asked the medical directors of Canadian ALS clinics about their approach to gastrostomy feeding in patients with ALS. This information was also requested in the newsletter of the Canadian ALS Research Network (CALNS). We asked two questions. Does the clinic have written centre-specific protocols to guide the timing of PEG placement in ALS patients? If a protocol existed we requested that they forward us any relevant documents. For centres that did not have written protocols we asked what steps are taken to determine candidacy and timing for placement of gastrostomy feeding tubes in

lieu of formal guidelines. The responses were aggregated in order to compare and contrast the practices across clinic sites.

RESULTS

A total of seventeen Canadian ALS clinics were contacted and ten centres provided a response. The results of the survey are summarized in Table 1. The open-ended questions led to variable amounts of detail in individual responses. One centre had centre specific written guidelines whereas the other nine did not. One of the ten responding centres was a francophone clinic. The remaining nine clinics were English speaking. All of the clinics were hospital affiliated. Nine of the ten responses commented on key decision-making criteria they consider in the decision to insert gastrostomy feeding tubes.

Most centres used a decline in respiratory function, dysphagia, weight loss or some combination of all three. Six clinics explicitly stated that they measure and consider a dropping FVC, a marker of respiratory decline, as a factor prompting the decision for feeding tube insertion. The FVC chosen ranged from >70% (with rapid decline) to <30% in special cases. One clinic reported inserting feeding tubes after tracheotomy and ventilation but stated this is a rare occurrence. Most recommend gastrostomy feeding at around FVC 50-60% of predicted. Swallowing impairment was reported as an important factor in decision-making by seven clinics but there was variation in how this was applied. Some clinics considered the number of aspiration events, others monitored prolonged mealtimes and patient and/or family concerns about swallowing. Two centres report regular use of swallowing assessments, either modified barium swallow or fiberoptic endoscopic evaluation of swallowing (FEES) to determine the extent of dysphagia and used this in their clinical decision making process. Five clinics reported weight loss in conjunction with, or independent of, other clinical factors could result in a referral for a feeding tube. Three centres used a quantifiable amount (>10% weight loss or <18.5 kg/m² BMI in one centre and >10% weight loss in two centres) as triggering a need for gastrostomy feeding. Two others stated weight loss was considered but done through subjective assessment such as patient report. Two centres explicitly stated that they follow published guidelines for management of gastrostomy feeding in ALS.

Psychological readiness to have a tube placed was commented on by three sites as significantly influencing the recommendation for tube placement. Some centres note that discussions regarding future gastrostomy feeding are brought up early in the course of the disease to prepare the patient for future decision-making. Three sites reported that they frequently insert tubes well before oral feeding is impacted – sometimes more than a year in advance. This was generally due to reducing respiratory function in the absence of swallowing impairment. One clinic emphasized they recommended advanced health care directives to their patients that specifically include tube feeding decisions.

The method of feeding tube insertion varied considerably from centre to centre. Three centres report using PEG, three centres radiologically inserted gastrostomy (RIG) and four did not comment. One centre noted that the expertise for RIG was not available, hence all procedures are PEG. One centre requires admission to hospital for the procedure, but that was not a general requirement for the centres that reported.

DISCUSSION

Weight loss and aspiration risks are concerns that can be adequately managed by gastrostomy feeding. The timing and criteria

Table 1: Canadian ALS clinic survey responses identifying which clinical factors prompt a referral for insertion of a feeding tube.

| Site | Protocol | FVC | Dysphagia | Weight loss | Method |
|------|----------|---|---|--|------------|
| 1 | No | 50-55% | Yes | >10% of weight loss | |
| 2 | No | <50% but will insert down to 30% | Yes - assessed by MBS, FEES or patient report | When significant | Radiologic |
| 3 | No | >50% | | | |
| 4 | No | | Yes | | Endoscopic |
| 5 | Yes | FVC <60% OR FVC >70% with one or more of the following: rapid decline in FVC, low ALSFRS score OR drop of >1 point per month, indicated wish for aggressive ventilation | Yes -including poor bulbar function at any FVC, prolonged meal time, ending meal prematurely due to fatigue | >10% weight loss OR BMI <18.5 at any FVC | Radiologic |
| 6 | No | >50% | Yes | | Endoscopic |
| 7 | No | | Yes | May prompt referral | |
| 8 | No | <60% with dysphagia OR respiratory symptoms in the absence of dysphagia | Yes - assessed by MBS or patient report | | Endoscopic |
| 9 | No | | | | |
| 10 | No | | | >10% of weight loss | Radiologic |

Notes: Clinic names have been removed. A blank entry denotes the respondent did not comment on this topic. FVC: Forced vital capacity. BMI: Body mass index kg/m². ALSFRS: ALS Functional Rating Scale. MBS: Modified barium swallow. FEES: Fiberoptic endoscopic evaluation of swallowing.

needed to insert a feeding tube is less clear. In lieu of good evidence there exists substantial variation in practice amongst Canadian ALS clinics.

Respiratory impairment, measured as FVC, was widely cited as prompting tube insertion. PEG placement requires mild sedation, which is thought to be hazardous in patients with compromised respiratory status. Currently the AAN practice parameter recommends PEG placement when FVC is greater than 50% predicted if dysphagia and weight loss are present. The parameter suggests caution in PEG insertion once the FVC is between 30-50%. Finally, it deems less than 30% predicted to be high risk.¹⁴ With less than 30% predicted, the parameter recommends palliative intravenous hydration and nasogastric feeding to supplement any tolerated oral intake.

Certainly the relationship between respiratory compromise and PEG insertion has received attention in the literature. The benchmark FVC values set by the AAN are supported by studies that have recommended for optimal safety and efficacy that PEG be placed before the FVC falls to 50% of predicted due to increased rate of decline after this point.¹⁹⁻²⁰ Likewise, studies have reported that longer survival was associated with higher FVC at time of PEG insertion.²¹⁻²² More recent literature complicates the picture, suggesting that PEG can be inserted at lower FVCs without impacting survival.²³⁻²⁶ Finally, assisting respiration during insertion, through non-invasive ventilator aids, can improve insertion outcomes in patients with severe respiratory muscle impairment.²⁷⁻²⁹ In our study six of the ten clinics reported using FVC to determine placement. Most felt comfortable placing PEG when FVC had fallen to 50-60% predicted. However, at least one clinic will perform gastrostomy tube insertion down to FVC 30% predicted. There were also differences in the likelihood that clinics would place feeding tubes well above the AAN benchmark of FVC 50%. Clearly respiratory involvement must be considered in the timing and placement of PEG but more research is needed to delineate the relationship.

Radiologically inserted gastrostomy (RIG) does not require sedation and can be an alternative to PEG when respiratory function is severely impaired. Studies that have compared outcomes of radiologic placed tubes with endoscopic placement are contradictory. Some studies have found radiologic placement to be more efficacious and better tolerated,³⁰⁻³¹ whereas, other studies found no significant difference in efficacy.^{16,32-33} While growing in popularity, RIG is not as widely available and therefore PEG is used more often. Only three of our ten responding clinics reported using RIG for their ALS population. One centre had used RIG in the past but discontinued this practice after “significant negative experiences.” Regardless of the ambiguity in the literature with respect to RIG and PEG, consensus is that both are more efficacious than naso-gastric insertion in terms of survival and complication rate.³⁴⁻³⁵ Despite higher rates of ulceration and discomfort, naso-gastric tubes can be used in the short term or when PEG/RIG are contraindicated.³⁶⁻³⁷

Other relevant criteria that have been identified in the literature as likely to play an important in feeding tube placement include an unintentional and accelerated weight loss (often described as a loss of >10%), dysphagia, low BMI (generally less than 18 kg/m²) and failure of longitudinal nutritional assessments.³⁷ Both weight status and dysphagia were identified in our survey as being considered by clinics in the decision making process. It is intuitive that both would play a role in the decision to supplement oral feeding. These criteria, like respiratory benchmarks, require

further research to understand what place they should take in the decision regarding gastrostomy feeding. Indicators of nutritional deficiency variably applied were identified as key elements of the evaluation of need for gastrostomy feeding in half of our reporting clinics, potentially reflecting uncertainty in how to integrate this information into the decision making process.

Though ALS clinics in Canada are known to be interdisciplinary, our study did not ask whether clinics have dedicated gastroenterologists, dieticians, or speech language pathologists available during the decision making process. This is of relevance as studies have suggested inclusion of inter-disciplinary nutrition support teams results in higher rates of insertion.³⁸ Once the decision is made to insert a feeding tube, dieticians and speech language pathologists help guide the choice of formula feed and infusion rate of feeds. This is another area of decision-making uncertainty as there are no ALS specific feeds or guidelines for artificial nutrition in ALS. Initial studies suggest that a high-carbohydrate hypercaloric enteral formula is ideal, tolerable, and safe but assessing the efficacy of specific feeds on disease progression is an area in need of further research.³⁹

Differences between clinic sites and the lack of written centre-specific protocols has the potential to result in discrepancies in the management of ALS based on geographical location and/or time of presentation. Paramount in the effort to resolving these divergent care plans is the need for quality evidence-based guidelines. In order for such guidelines to be drafted there exists a need for more rigorous and ALS-specific research studies that examine the timing and insertion criteria for the placement of PEG.

This study used open-ended questions directed to medical directors to obtain information regarding practice in Canadian ALS clinics. A weakness of the study is a lack of data regarding actual practice, which might be divergent from the reported practice principles. The responses may not reflect which factors are deemed important in the nutritional management of all patients managed in the responding clinics. We did not ask for a hierarchical list of deciding factors in all patients and it is possible all clinics use some or all of the identified factors in different patient circumstances. A study analyzing clinic data on the key clinical and laboratory indicators that trigger the recommendation of gastrostomy feeding would most accurately describe the practice in Canadian ALS clinics.

Based on published guidelines and clinical practice highlighted in this report, patients with ALS should have an evaluation of their nutritional status soon after diagnosis and there should be reevaluation at each clinic visit.¹⁴ The key parameters to assess include symptoms of dysphagia, BMI, and FVC. Patients should be provided with information regarding gastrostomy feeding early in their care. Patients with symptoms or laboratory evidence of dysphagia should be considered for gastrostomy. Likewise, patients with significant weight loss should also be considered for gastrostomy. Patients with failing respiration should be counseled to consider gastrostomy placement before respiratory function becomes too poor to safely insert a tube. If respiratory function is already poor, such as an FVC <50% when the decision to place a gastrostomy tube is made, then non-invasive ventilation around the time of insertion and the alternative of RIG should be considered.

In addition to more quantitative research into PEG criteria, there is a role for qualitative patient perspectives. To date, there is

little published evidence regarding quality of life with respect to PEG insertion in patients with ALS. Preliminary research suggests that a feeding tube does give the patient a greater sense of control but may lead to increased anxiety.⁴⁰ This might be of particular relevance, as there seems to be a trend to recommend PEG earlier than required to avoid potential complications of late-placement. More quality of life studies are needed. Our study focused on the medical factors influencing the decision-making process for a referral to a feeding tube. For placement to take place, it requires a separate decision-making process on the part of the patient. Growing literature suggests that factors involved in the patient's decision are even more complex and multi-faceted.^{41,42} Such decisions may benefit from an individualized approach to referral rather than an algorithmic approach.⁴³ The patient experience before, during and after insertion of a gastrostomy tube is an essential component of developing guidelines for what is essentially a palliative procedure. Information from patients about perceived nutritional needs; desires regarding timing of tube placement; benefits and difficulties noted after tube placement would all be important for development of effective guidelines. These questions may be answered by using qualitative research techniques.

DISCLOSURES

Timothy Benstead, Caitlin Jackson-Tarleton, and Desmond Leddin do not have anything to disclose.

REFERENCES

1. Vaisman N, Lusaus M, Nefussy B, et al. Do patients with amyotrophic lateral sclerosis (ALS) have increased energy needs? *J Neurol Sci.* 2009;279:26-9.
2. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ. Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. *Am J Clin Nutr.* 1996;63:130-7.
3. Leigh PN, Ray-Chaudhuri K. Motor neuron disease. *J Neurol Neurosurg Psychiatry.* 1994;57:886-96.
4. Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. *J Neurol.* 1995;242:695-8.
5. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. *Neurology.* 1999;53:1059-63.
6. Desport JC, Preux PM, Magy L, et al. Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. *Am J Clin Nutr.* 2001;74:328-34.
7. Desport JC, Torny F, Lacoste M, Preux PM, Couratier P. Hypermetabolism in ALS: correlations with clinical and paraclinical parameters. *Neurodegener Dis.* 2005;2:202-7.
8. Funalot B, Desport JC, Sturtz F, Camu W, Couratier P. High metabolic level in patients with familial amyotrophic lateral sclerosis. *Amyotroph Lateral Scler.* 2008;16:1-5.
9. Stambler N, Charatan M, Cedarbaum JM. Prognostic indicators of survival in ALS. ALS CNTF Treatment Study Group. *Neurology.* 1998;50:66-72.
10. Chio A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. *Amyotroph Lateral Scler.* 2009;10:310-23.
11. Jawaid A, Murthy SB, Wilson AM, et al. A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS. *Amyotroph Lateral Scler.* 2010;11:542-8.
12. Limousin N, Blasco H, Corcia P, et al. Malnutrition at the time of diagnosis is associated with a shorter disease duration in ALS. *J Neurol Sci.* 2010;297:36-9.
13. Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. *J Neurol Neurosurg Psychiatry.* 2011;82:628-634.

14. Miller RG, Jackson CE, Kasarskis EJ, et al. Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2009;73:1218.
15. EFNS Task Force on Diagnosis and Management of Amyotrophic Lateral Sclerosis: EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force. *Eur J Neurol*. 2012;19:360-75.
16. Katzberg HD, Benatar M. Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease. *Cochrane Database Syst Rev*. 2011 (1):CD004030. doi: 10.1002/14651858.CD004030.pub3.
17. Allen JA, Chen R, Ajroud-Driss S, et al. Gastrostomy tube placement by endoscopy versus radiologic methods in patients with ALS: a retrospective study of complications and outcome. *Amyotroph Lateral Scler Frontotemporal Degener*. 2013;14:308-14.
18. Shaw AS, Ampong MA, Rio A, McClure J, Leigh PN, Sidhu PS. Entristar skin-level gastrostomy tube: primary placement with radiologic guidance in patients with amyotrophic lateral sclerosis. *Radiology*. 2004;233:392-3.
19. Kasarskis EJ, Scarlata D, Hill R, et al. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. *J Neurol Sci*. 1999;169:118.
20. Andersen PM, Borasio GD, Dengler R, et al. Good practice in the management of amyotrophic lateral sclerosis: clinical guidelines. An evidence-based review with good practice points. *Amyotroph Lateral Scler*. 2007;8:195.
21. Chio A, Finocchiaro E, Meineri P, Bottacchi E, Schiffer D. Safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS: ALS Percutaneous Endoscopic Gastrostomy Study Group. *Neurology*. 1999;53:1123-5.
22. Desport JC, Preux PM, Truong CT, Courat L, Vallat JM, Couratier P. Nutritional assessment and survival in ALS patients. *Amyotroph Lateral Scler*. 2000;1:91-6.
23. Gregory S, Siderowf A, Golaszewski AL, McCluskey L. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. *Neurology*. 2000;58:485-7.
24. Spataro R, Ficano L, Piccoli F, La Bella V. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: effect on survival. *J Neurol Sci*. 2011;304:44-8.
25. Sarfaty M, Nefussy B, Gross D, Shapira Y, Vaisman N, Drory VE. Outcome of percutaneous endoscopic gastrostomy insertion in patients with amyotrophic lateral sclerosis in relation to respiratory dysfunction. *Amyotroph Later Scler Frontotemporal Degener*. 2013;14:528-32.
26. Dorst J, Dupuis L, Petri S, et al. Percutaneous endoscopic gastrostomy in amyotrophic lateral sclerosis: a prospective observational study. *J Neurol*. 2015;262:849-58.
27. Boitano LJ, Jordan T, Benditt JO. Non-invasive ventilation allows gastrostomy tube placement in patients with advanced ALS. *Neurology*. 2001;56:413-4.
28. Gregory S, Siderowf A, Golaszewski AL, McCluskey L. Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. *Neurology*. 2002;58:485-7.
29. Sancho J, Servera E, Chiner E, et al. Noninvasive respiratory muscle aids during PEG placement in ALS patients with severe respiratory impairment. *J Neurol Sci*. 2010;297:55-9.
30. Thornton FJ, Fotheringham T, Alexander M, Hardiman O, McGrath FP, Lee MJ. Amyotrophic lateral sclerosis: enteral nutrition provision – endoscopic or radiologic gastrostomy? *Radiology*. 2002;224:713-7.
31. Blondet A, Lebigot J, Nicholas G, et al. Radiologic versus endoscopic placement of percutaneous gastrostomy in amyotrophic lateral sclerosis: multivariate analysis of tolerance, efficacy and survival. *J Vasc Interv Radiol*. 2010;21:527-33.
32. Desport JC, Mabrouk T, Bouillet P, Perna A, Preux PM, Couratier P. Complications and survival following radiologically and endoscopically-guided gastrostomy in patients with amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord*. 2005;6:88-93.
33. ProGas. Gastrostomy in patients with amyotrophic lateral sclerosis: a prospective cohort study. *Lancet Neurol*. 2015;14:702-9.
34. Scott AG, Austin HE. Nasogastric feeding in the management of severe dysphagia in motor neurone disease. *Palliat Med*. 1994;8:45-9.
35. Gomes CA, Andriolo RB, Bennett C, et al. Percutaneous endoscopic gastrostomy versus nasogastric tube feeding for adults with swallowing disturbances. *Cochrane Database Syst Rev*. 2015;5:CD008096. doi: 10.1002/14651858.CD008096.pub4.
36. Norton B, Homer-Ward M, Donnelly MT, Long RG, Holmes GK. A randomized prospective comparison of percutaneous endoscopic gastrostomy and nasogastric tube feeding after acute dysphagic stroke. *BMJ*. 1996;312:13-6.
37. Heffernan C, Jenkinson C, Holmes T, et al. Nutritional management in MND/ALS patients: an evidence based review. *Amyotroph Lateral Scler*. 2004;5:72-83.
38. Zhang L, Sanders L, Fraser R. Nutritional support teams increase percutaneous endoscopic gastrostomy uptake in motor neuron disease. *World J Gastroenterol*. 2012;18:6461-7.
39. Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, et al. Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet*. 2014;383:2065-72.
40. O'Farrell BM, Strong MJ, Zou GY, Rowe AM, The ALS Research Consortium of Canada. The impact of enteral nutritional support on the quality of life of ALS patients and their primary caregivers. *Amyotroph Lateral Scler Frontotemporal Degener*. 2005;6:36-8.
41. Martin NM, Landau S, Janssen A, et al. Psychological as well as illness factors influence acceptance of non-invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): A prospective population study. *Amyotroph Lateral Scler Frontotemporal Degener*. 2014;15:376-87.
42. Stavroulakis T, Baird WO, Baxter SK, Walsh T, Shaw PJ, McDermott PJ. Factors influencing decision-making in relation to timing of gastrostomy insertion in patients with motor neurone disease. *BMJ Support Palliat Care*. 2014;4:57-63.
43. Greenaway LP, Martin NH, Lawrence V, et al. Accepting or declining non-invasive ventilation or gastrostomy in amyotrophic lateral sclerosis: patients' perspectives. *J Neurol*. 2015;262:1002-1013.